Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform
Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...
Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...
Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
StarryGene Initiates Phase I Clinical Trial for XMVA09 Gene Therapy in wAMD
StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced...
Gilead’s Lenacapavir Shows 100% Efficacy in Phase III HIV PrEP Study
Gilead Sciences Inc. (NASDAQ: GILD), a U.S. biopharmaceutical company, has announced topline results from the...
Hefei Airport Port Designated as Drug Import Port by Chinese Authorities
Hefei Airport Port, located in the city of Hefei, China, has been designated as a...
Zai Lab’s Partner Argenx Receives FDA Approval for CIDP Treatment Vygart Hytrulo
Argenx SE (NASDAQ: ARGX), the U.S. partner of China-based biopharmaceutical company Zai Lab Ltd (NASDAQ:...
Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform
Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...
METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery
METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...
Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...
Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation
Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Shineco Inc. Acquires 80% Stake in ‘Internet+Medical Care’ Platform Meitong Tech for USD 20 Million
Shineco Inc. (NASDAQ: SISI), a U.S.-based company, has signed an investment agreement with Beijing Dongfang...
Zhangzhou Pien Tze Huang’s PZH2113 Receives NMPA Clinical Trial Approval for Lymphoma Treatment
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436), a renowned traditional Chinese medicine (TCM)...
Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial
Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly...
Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...